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Background: Research literature consistently documents that scientifically based therapeutic recommendations are
not always followed in the hospital or in the primary care setting. Currently, there is evidence that some general
practitioners in Australia are not prescribing appropriately for patients diagnosed with 1) hypertension (HT) and 2)
chronic heart failure (CHF). The objectives of this study were to improve general practitioner’s drug treatment
management of these patients through feedback on their own prescribing and small group discussions with peers
and a trained group facilitator. The impact evaluation includes quantitative assessment of prescribing changes at 6,
9, 12 and 18 months after the intervention.
Methods: A pragmatic multi site cluster RCT began recruiting practices in October 2009 to evaluate the effects of a
multi-faceted quality improvement (QI) intervention on prescribing practice among Australian general practitioners
(GP) in relation to patients with CHF and HT. General practices were recruited nationally through General Practice
Networks across Australia. Participating practices were randomly allocated to one of three groups: two groups
received the QI intervention (the prescribing indicator feedback reports and small group discussion) with each
group undertaking the clinical topics (CHF and HT) in reverse order to the other. The third group was waitlisted to
receive the intervention 6 months later and acted as a “control” for the other two groups.
De-identified data on practice, doctor and patient characteristics and their treatment for CHF and HT are extracted
at six-monthly intervals before and after the intervention. Post-test comparisons will be conducted between the
intervention and control arms using intention to treat analysis and models that account for clustering of practices
in a Network and clustering of patients within practices and GPs.
Discussion: This paper describes the study protocol for a project that will contribute to the development of
acceptable and sustainable methods to promote QI activities within routine general practice, enhance prescribing
practices and improve patient outcomes in the context of CHF and HT. Trial registration: Australian New Zealand
Clinical Trials Registry (ANZCTR), Trial # 320870.* Correspondence: mcardonamorrell@nps.org.au
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Pharmacological management of hypertension (HT)
reduces cardiac events, stroke, hospitalisations, health
care costs and improves quality of life for hypertensive
patients (HT) [1,2]. Appropriate treatment of chronic
heart failure (CHF) with ACE inhibitors, angiotensin II
receptor antagonists, beta-blockers and diuretics have
also shown benefits in terms of survival and averted hos-
pitalisations, irrespective of the underlying cause [3,4].
Australian [5,6] and overseas studies report that treat-
ment of HT [7-15] and heart failure [16-19] are not well
aligned with evidence-based guidelines. For example, in
Australia, fewer than 50 percent of heart failure patients
admitted to any of three hospitals in Tasmania were
being treated with target doses of the recommended
drugs [18]. Among Australian patients attending general
practice, under-prescribing for heart failure was found
both in terms of the number receiving the recom-
mended drugs and the dosage levels [20,21]. A national
Australian survey reported the prevalence of untreated
HT at 15.2% [13] and four consecutive GP audits of self-
reported prescribing practices concluded that there was
room for improvement in the management of hyperten-
sive patients with co-morbidities [14].
The consequences of suboptimal care for these condi-
tions include increased hospitalisation, higher mortality,
[22,23] greater symptom severity [23] and increased
costs to the health care system [22,24-26]. It is clear that
best practice guidelines alone cannot secure improve-
ments in practice [5,27-29].
Educational interventions and quality improvement
(QI) activities can improve the quality of prescribing in
general practice settings [5,30]. Multi-faceted interven-
tions, particularly those involving interactive educational
sessions for healthcare providers, and/or patient educa-
tion are reported to be more effective than passive inter-
ventions [10,31-37]. Multi-faceted interventions have
shown modest improvements in patient outcomes such
as the proportion of patients meeting blood pressure tar-
gets [8,23] and also changes in prescribing patterns such
as the proportion CHF patients receiving a beta blocker
or taking target doses of ACE inhibitors [38].
In evaluating these types of complex QI interventions,
pragmatic randomised controlled trials (RCTs) are emer-
ging as a way of bridging the gap between traditional
RCTs which have a good internal validity and observa-
tional studies, which have good external validity [39-41].
The Prescribing Data in General Practice Demonstra-
tion (PDGPD) project uses a multifaceted complex inter-
vention aimed to improve GP prescribing behaviour for
patients with HT and CHF in alignment with clinical
practice guidelines.
This paper provides details of the intervention compo-
nents and protocol, and methods and measurementsused to evaluate the impact of the quality improvement
initiative.
The project is a partnership between National Prescribing
Service (also known as NPS MEDICINEWISE), an inde-
pendent, evidence-based organisation delivering continuing
education for health professionals to enable better decisions
about medicines and medical tests [42], and the Australian
General Practice Network (AGPN), the body representing a
network of 111 local general practice networks (henceforth
referred to as Networks) which covers 90% of registered
GPs in the country [43].
The project governance included several external and
internal groups that oversee various aspects of the pro-
ject including the evaluation and the implementation.
(see Additional file 1: Appendix 1).Methods/Design
Aims of the intervention
The aim of the PDGPD intervention is to improve pre-
scribing behaviour and clinical outcomes for patients
with HT and CHF. These topics were chosen due to the
existing gap between evidence and actual practice and
the potential benefits resulting from changes in the man-
agement of patients. A list of terms used in clinical prac-
tice software to describe these two diagnoses can be
found in Appendix 2 (Additional file 2). The quality im-
provement activity allows GPs to use their own prescrib-
ing data for ongoing review of patient management and
for peer comparison.The intervention
The intervention included facilitated discussion about
these conditions within general practices recruited across
Australia using feedback about their patient management
extracted from practice clinical software. This multi-
faceted intervention was designed to be implemented
from June 2009 with follow-up until December 2011.
We used a multifaceted intervention based upon
recognised quality improvement strategies that are
implemented over a 12 month time frame. The inter-
vention in this project consisted of a series of quality
improvement activities (Figure 1). Data cleaning and
recording of relevant clinical information was actively
encouraged two months prior to the first clinical
meeting among all practices in the study (step 1) to
enable extraction of reliable information from relevant
database fields. An initial facilitated group discussion
(clinical meeting) was held by GPs within the practice
with a trained project facilitator on treatment of CHF
and HT (step 2). A data extraction and report tool
supplied immediate feedback from the practice clinical
software system regarding each GP’s own prescribing,
as well as the results for the whole practice and the
Step 2. Assess data and plan actions 
At initial clinical meeting, review current clinical indicator results and compare with  
peers.  Identify patients who will most benefit from review.  Agree on number of 
patients to review and strategies for change. 
Step 3. Implement changes 
Practice to implement agreed strategies for change over the agreed time period between 
clinical meetings.  Review patients identified by indicators reports and adjust treatment  
where appropriate. 
Step 4.  Assess data and progress 
At the follow-up clinical meeting, assess current clinical indicator results progress.   
Compare with local and national aggregate clinical indicator results.  Agree on next 
steps: additional patients to review and strategies for change. 
Step 5. Implement changes 
Practice to implement agreed strategies for change over the agreed time period. Review 
patients identified by indicators reports and adjust treatment where appropriate. 
Step 6. Continue the quality improve activity 
Assess current data, reflect on progress and plan next quality improvement cycle. 
Step 1. Improve data quality 
With the practice staff, examine data quality reports and baseline results and identify  
inactive or deceased patients.  Find unrecorded cases and ensure conditions and BPs are 
coded in correct fields and current medication lists are accurate.  Update medical records 
where necessary. 
Preliminary Steps 
Introductory meeting with practice staff (practice managers and practice nurses and 
GPs in some instances) to fully explain the project, install and demonstrate the data 
extraction and reporting tool. 
Figure 1 Quality improvement intervention process.
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ical meeting.
Identification of patients suitable for clinical review oc-
curred after the initial clinical meeting (step 3). A follow-up facilitated peer group clinical meeting was held around
two to three months after the first meeting (step 4) to
check progress on the patients prioritised for review of
therapy and any changes to the prescribing data feedback.
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The aim of the evaluation of the PDGPD project was to
estimate the impact of the quality improvement inter-
vention on prescribing practice and to measure short
term changes in blood pressure in patients with HT and
CHF. The evaluation used a pragmatic randomised clus-
ter controlled trial design.
Study groups and randomisation
Practices agreeing to participate were registered and ran-
domly allocated automatically into one of the three
study groups (either into one of the two intervention
groups or into the wait-control group) using computer
generated random numbers. Block randomisation was
used to enable balanced representation of practices in
each of the Networks. The randomisation determined
the sequence of exposure to the intervention as follows
(see Figure 2):
Group 1 received the intervention for the CHF topic in
the first six months and the HT topic in the
next six months. In the first six months, this
group also acts as the topic control group for
group 2.
Group 2 received the intervention for the HT topic in
the first six months and the CHF in the next
six months and also acts as topic control
group for group 1 in the first six months.
Group 3 is a wait-control for groups 1 and 2 in the first
six months and did not receive any
intervention in the first six months. This
group received the intervention after six
months and implemented the 2 topics
sequentially – the order of topics was left up
to the practice involved to choose. This group
acts as ‘true’ control for groups 1 and 2 in the
first six months.
As it is well recognised with educational interventions
delivered at the practice level [40,44], it was not feasible
to blind participating general practitioners and practices
to the intervention because they had to be trained on
the software installation and needed to be notified of
their topic allocation in order to carry out the required
quality improvement activity.
The expected time frame for the research was 2 years,
including the recruitment and training time and
18 months of follow-up; data collection for baseline and
six months are currently being analysed.
Outcome assessment
Diagnoses of HT and CHF were based on GP clinical de-
cision entered in their database. Clinical indicators of
appropriate and safe prescribing behaviour and bloodpressure control were used as measures of impact at
various stages of the intervention. This type of indicator
is widely used in the medical literature, and Australian
doctors are familiar with the concept from their expos-
ure to locally relevant educational resources and inter-
ventions extracting data from their medical software for
other quality improvement initiatives [45-47].
The impact of the intervention was measured by two
primary prescribing outcomes for each condition tar-
geted by the intervention and five secondary prescribing
outcomes relating to these two clinical topics. These
were largely based on the prescribing indicators used in
the feedback reports to the GPs. For details of the medi-
cines covered see (Additional file 3: Appendix 3). Hos-
pital admission for heart failure was not used as a
clinical outcome indicator in this study because the pre-
scribing software database does not link to the data col-
lection for hospital admitted patients and does not
contain coded fields for this information.
Primary prescribing indicators
Hypertension
Proportion of adult patients with a diagnosis of HT who
have suboptimal control of blood pressure as follows:
a. Proportion of adult patients with HT and using at
least one antihypertensive drug, whose latest blood
pressure is 140 / 90 mm Hg or higher
b. Proportion of adult patients with HT and coronary
heart disease, diabetes, chronic kidney disease, stroke
or transient ischaemic attacks (TIA), whose latest
blood pressure is 130 / 80 mm Hg or higher
Chronic heart failure
Proportion of adult patients with CHF receiving appro-
priate treatment, ie:
a. using an ACE inhibitor or angiotensin II-receptor
antagonist
b. using an ACE inhibitor or angiotensin II-receptor




1. Proportion of adult patients with HT using a
prohypertensive drug whose latest blood pressure is
140 / 90 mm Hg or higher (see Additional file 3:
Appendix 3)
2. Proportion of adult patients using an ACE inhibitor
or angiotensin II-receptor antagonist, who are
concurrently using a systemic nonsteroidal
anti-inflammatory drug and a diuretic
General Practice Networks recruit practices
Cluster random allocation of practices  to sequence of education interventions
Group 1: CHF Topic
Data extraction
Group 2: HT Topic
Data extraction








 for all groups
1st clinical meeting: CHF
HT Topic CHF Topic HT or CHF Topic
Time 12 m
data extraction 
for all groups   
2nd clinical meeting: HT or CHF




for all groups 
2
nd
 clinical meeting:  CHF or HT





2nd clinical meeting: CHF
1st clinical meeting: HT
2nd clinical meeting: HT
1st clinical meeting: HT
2nd clinical meeting: HT
1st clinical meeting: CHF
2nd clinical meeting: CHF
1
st
 clinical meeting: HT or CHF
1st clinical meeting:  CHF or HT
Time 9 m
  data extraction 
for all groups
Time 3 m
   data extraction 
for all groups
Time 15 m
  data extraction 
for all groups
Figure 2 Evaluation using a cluster randomised controlled design. Group allocation and timeframes for data extraction and clinical
meetings.
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patients with and without co-morbidities (i.e.
diabetes, CHD, chronic kidney disease, stroke or TIA)
Chronic Heart Failure
1. Proportion of adult patients with CHF using an ACE
inhibitor below the recommended dose2. Proportion of adult patients with CHF using a drug
that may exacerbate the disease (see Additional file 3:
Appendix 3)
The clinical indicators used in this study were devel-
oped in consultation with clinical experts, GPs, phar-
macists, consumers and policy makers via focus
groups.
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was made on the basis of their construct validity, face
validity and operability or availability for data extraction
from routine collections. Most of the suggested indica-
tors were adopted from a previously published NPS
manual [45] or NPS audits. A comprehensive review of
the evidence relating to each indicator was conducted to
establish construct validity. Refinement to ensure face
validity was undertaken during a large workshop with
GPs and other potential users. Using a simple question-
naire with a Likert scale, participants were asked to rate
the accuracy of the indicators for measuring good pre-
scribing practice, the usefulness for identifying patients
receiving suboptimal treatment, and the usefulness for
comparing their own prescribing practice with that of
other GPs.
Final indicator definitions were decided by consensus
using the above evidence during clinical reference group
meetings, with input from expert Australian GPs and
other advisory or steering groups where necessary.
Final selection of 9 indicators from a set of 82 poten-
tial clinical indicators was followed by field testing. The
indicators were included in the study if there was evi-
dence of their potential to improve patient care in the
general practice setting, and they could be automatically
extracted from general practice clinical software. Blood
pressure measurements used in this study were those
taken during the course of routine clinical care. All
blood pressure measurements available in coded fields
were retrieved at each interval but the latest available
blood pressure recorded for each patient within 12
months of the data extraction was generally used to de-
termine the latest blood pressure level; and up to 12
blood pressure readings per patient in the past year were
used to estimate the mean for the practice.
Data collection for the impact evaluation
The extraction tool enables de-identification of GP and
patient data, encryption and transfer of information to a
secure NPS file transfer site for the evaluation.
Data extracts to estimate indicators for evaluation by
group allocation was planned to occur every three
months after the initial clinical meeting.
Sample Size estimations
Sample sizes were calculated with an assumed intra-
cluster correlation of 0.08 at the 80% power and 5%
significance level using the University of Aberdeen
sample size calculator, (version 1.0.2) which adjusts for
the clustering of GPs and patients in practices [48].
Estimates for the ICC and other parameters were
based on previous studies and analysis of data from a
sample of general practices [49]. With more than one
primary outcome to be measured, the sample sizerequired for the trial had to be powered to detect
changes for the condition with lower prevalence. In
Australian general practice, we applied the CHF clin-
ical indicators as the basis of the sample size calcula-
tions (estimated prevalence: 1%-4.1% for CHF vs. 10%-
44% for HT) [50-52]. Data previously collected from
an Australian GP panel source,[49] were used for the
following calculations. Assuming each of the GPs saw
at least half of their patient clientele in a year, it was
estimated that around 3% of GPs patient population
had CHF and that there are 7200 active adult patients
in an average 3 GP practice, of which 86 patients with
CHF were expected to visit the practice during the
first 6 months of the study. For a three-arm study
with ICC= 0.08, the total number of practices required
to show this difference is 99. Further, based on previ-
ous Australian and overseas experiences of GP or
practice recruitment in trials and surveys [19,53,54],
with an estimated drop out rate of 40-50% of all clus-
ters (practices), at least 180 practices were required to
identify both sufficient cases of CHF (the smaller pa-
tient group) and observable changes such as 10% abso-
lute increase in prescribing of ACE inhibitors and 15%
absolute increase in prescribing of beta blockers.
Eligibility criteria for Networks, practices and GPs
To be eligible to participate, a Network had to agree to
promote the study to their practices and GPs, be able to
recruit a minimum of 7 and a maximum of 15 general
practices, and have the capacity to appoint appropriate
personnel (project facilitators and other relevant staff )
to support the quality improvement intervention. For
practices to be eligible, the practice principal GP had to
consent to allow the installation of the data software ex-
traction tool and consent for the data to be securely
transferred for analysis. Consent was obtained from GPs
participating in the PDGPD activities.
Incentives for GPs, practices and Networks
GPs participating in two facilitated peer group clinical
meetings and undertaking a review of their patients
are eligible for mandatory continuing professional de-
velopment points recognised by the Royal Australian
College of General Practice and the Australian College
of Rural and Remote Medicine. This quality prescrib-
ing initiative also makes the practice eligible for pay-
ment as part of the Australian Government’s Practice
Incentives Program.
The funds provided to the Networks to deliver the
project were deliberately weighted to ensure Networks
recruited and retained the required minimum number of
practices for the duration of the project. Networks were
requested to provide $A500 to each practice to assist
with data cleaning processes at the project start.
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Recruitment of GP practices occurred in two stages. In
stage 1, Networks were recruited through a call for
Expressions of Interest from NPS and AGPN to recruit
practices and deliver the intervention. In stage 2, Net-
works recruited practices and GPs to participate in the
study and employed project facilitators to deliver and
co-ordinate the intervention in participating practices in
their Network.
Project facilitator training
Two 2-day facilitator training workshops were delivered
by NPS at the study start to give project facilitators a clear
understanding of the Project, its aims, their roles and re-
sponsibilities and principles of research design, privacy
issues and project implementation. Clinical knowledge of
management of patients with HT and CHF was another
important component. The focus then turned to develop-
ing skills in communication, negotiation and persuasion,
group facilitation, problem solving, facilitating decision
making, and change management. Data management
skills covered demonstration of the software installation,
data collection and cleaning, data transfer and storage and
data interpretation as well as hands on use of the data ex-
traction tool and practical examples on how to improve
data quality. On-going monthly teleconferences with
groups of facilitators were also established to support
facilitators in the field.
Data Extraction and data cleaning
A third party software tool was used to extract prescrib-
ing data from general practices. The tool was developed
to: (1) provide clinical indicator reports to measure the
clinical indicators; (2) provide data quality reports to
identify missing or incorrect clinical data to ensure ac-
curate calculation of clinical indicator reports; and (3)
enable data extracts at baseline, and at regular intervals
through the intervention, in order to evaluate changes in
prescribing over the intervention period. The data ex-
traction tool was developed over a period of 18 months
and included functional specification development, soft-
ware development, testing and piloting in general prac-
tice. The functional specifications included definitions
for where data is stored in clinical software; how the
data is coded or recorded, and the algorithms for calcu-
lating the clinical indicator.
A pre-intervention phase of two months included the
installation of the data extraction software, training of
practice staff in its use for data cleaning, upload and
transfer (see Additional file 4: Appendix 4). Data quality
reports obtained from the data software extraction tool
allowed the practice to clean their data by improving the
quality of coding and completeness of fields in the prac-
tice clinical software during these first two months.Clinical indicator reports were collected from the GP
clinical software just before the initial clinical meeting
and every quarter. They were used within the practices to
give individual GP and practice-level feedback. Evaluation
data extracts retrieved anonymised data for patients with
relevant conditions. This complete data subset with
intervention-relevant variables extracted was transferred
to a secure data repository located at NPS for the impact
evaluation.
Data Analysis
The unit of randomisation is the practice and unit of
analysis is the patients accounting for clustering by prac-
tice (using Proc surveyfreq in SAS Enterprise Guide v4).
The following analysis will be presented comparing the
three groups:
a. Successive cross-sectional analyses at six-month
intervals which include any practice with patient data
available at each point. This will be to estimate point
prevalences of each indicator before and after the
intervention. Comparisons of practice proportions
of patients meeting the individual
guideline-recommended indicators (with 95%
confidence intervals) across intervention groups will
be conducted using χ2 statistics.
b. Longitudinal (cohort) estimates of changes in
indicators occurring between time points, based on
data from patients who had at least one visit before
baseline and at least one visit following the
intervention.
c. Sequential indicators will be calculated where
changes in prescribing behaviours are measured only
for patients not meeting guideline-driven indicators
in the preceding 6-12-month period (e.g. proportion
of CHF patients using an ACE inhibitor or
angiotensin II-receptor antagonist at 6 months, out
of those not receiving this treatment at baseline).
This approach will show whether the intervention
modified prescribing behaviour using a denominator
where patients have scope for improvement.
Changes in the proportion of patients appropriately
prescribed target medicines before and after the interven-
tion will also be presented, with χ2 statistics for categor-
ical measures (e.g. on heart failure medication or not at
each time point), and significance testing of before and
after the intervention effects within intervention groups
based on paired t tests for continuous measures (e.g.
mean blood pressure change) within groups and with a
p-level of ≤0.01 considered to be statistically significant.
Supplementary regression analyses of the cohort will
identify predictors of improved prescribing at 12 and
18 months after controlling for other possible
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practice size, rural/urban location, socio-economic level
of the area, percentage female doctors, mean years of GP
experience. Post-test comparisons will be conducted be-
tween the intervention and wait-control arms using
intention to treat analysis [55] and models that account
for the non-independence of observations due to the
clustering of practices in a Network and clustering of
patients within practices and GPs. Separate binary logis-
tic regression models will be analysed for CHF and HT
adjusting for clustering effects of practice and GP [56].
Stepwise regression techniques will be used. Odds ratios
will be used as the common measure of the estimated ef-
fect of the intervention and the independent effect of ex-
planatory variables. To account for chance imbalance
across intervention groups,[57] explanatory variables for
each model will include patient characteristics, practice
characteristics, and location of the Network. The
researchers analysing the impact of the intervention on
study outcomes have no contact with Networks or prac-
tices involved and are blinded to allocation group code at
the baseline analysis stage.
Ethical considerations
The study obtained ethics approvals from the Royal
Australian College of General Practitioners Human
Research Ethics Committee (approval number RACGP
08/007).
Participation of GPs and practices was voluntary and
subject to informed consent for participation by the
practice and the GP prior to any whole-of-practice data
extraction. Although patients are not direct participants
in the study, their non-identifiable data is being used to
evaluate the intervention with GPs. Patients are notified
via a poster in the practice that the practice is participat-
ing in a quality improvement initiative and can opt out
of the process of their de-identified information being
sent to NPS for analysis by notifying their doctor. After
recording withdrawal of consent, their data are removed
and not extracted by the data extraction tool used to
collect the evaluation data.
Members of the research and evaluation team analys-
ing the data have access only to de-identified informa-
tion for Networks, practices and patients. Staff involved
in data decryption do not participate in the analysis and
all staff are required to sign a confidentiality agreement.
Discussion
The challenges of implementing and evaluating real-
world interventions to improve health and professional
behaviours are well documented [27,30,58-60]. Participa-
tion of doctors in educational interventions and their will-
ingness to accept evaluation audits rely on practice-based
and doctor-based factors not often reported in theliterature.[53,54] A doctor’s prescribing behaviour also
depends on personal characteristics, years of experience,
motivation, marketing strategies used by pharmaceutical
industries, demands from society and patients, knowledge
of guidelines, confidence and regulatory actions [34,60-
63].
There are methodological difficulties in designing sound
evaluations to identify the impact that context can have
on success of prescribing interventions [54,57,64]. For in-
stance, GPs prescribe in apparent conflict with guidelines
for reasons that are complex, and can vary from previous
experience with medical misadventures, to patient-factors
such as patient age, education, ethnicity, social class, likely
compliance and lifestyle considerations. [62,64] Uncer-
tainty of intervention effectiveness is further compounded
by the bias in reporting of studies and the inability to attri-
bute success to individual intervention components
[23,65].
The evaluation of PDGPD project uses a pragmatic
cluster RCT design, where one of two interventions or
control status is randomly assigned to individual prac-
tices. A pragmatic cluster-randomised trial is considered
an appropriate research design in public health and edu-
cational interventions as it allows more variability in the
entry criteria, reduces the impact of contamination within
groups, and provides administrative convenience for im-
plementation [39,40,57,66]. PDGPD will have access to
several data points to investigate immediate and mid-
term impact of the quality improvement initiative. How-
ever, several potential weaknesses in the design of
PDGPD are acknowledged: first, the voluntary nature of
GP participation in the cluster design where a practice
[cluster] agreed to participate but not all GPs in the prac-
tice received the intervention. This may lead to dilution
of the intervention effect when data from all patients seen
by all GPs in the practice are analysed. The intervention
is designed to encourage GPs to communicate key mes-
sages with other non-participating GPs in the practice
and to welcome non-enrolled GPs to attend clinical dis-
cussion meetings within the same intervention group; fur-
ther, the impact of participation rate by practice can be
incorporated in the regression analysis model. Second,
the cross-over design (Figure 1) where the same facilitator
delivers one intervention after another in the same prac-
tice and one topic in one intervention practice and the
competing topic in another practice carries the risk of
cross-contamination; allocation of clinical topic order was
done at random and facilitators were trained at focusing
on discrete messages of one topic at a time. Thirdly, the
wait-control group provides pre-intervention comparisons
only for the first six months of the trial; for practical rea-
sons in non-research settings (i.e. need for an interven-
tion in exchange for participation) the control group
received the intervention six months later.
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an intervention to align GP prescribing behaviours with
practice guidelines over time in Australia. Further, the
evaluation will report the extent to which practice char-
acteristics (such as rural/urban location and total number
of active patients) and patient profile, (such as age, sex,
presence of co-morbidities and number of medications)
may affect the likelihood of adopting these prescribing
changes. The ability to adopt or adapt evidence-based
programs with fidelity in general practice is an important
aspect to identify feasibility, acceptability and sustainabil-
ity of such programs in the future. A comprehensive suite
of qualitative studies have been developed for this project
to assess such issues. Details on the qualitative evalu-
ation components of the PDGPD will be described
elsewhere.
Finally, the PDGPD project is expected to bring the
following benefits:
 Improved care and outcomes for patients with heart
failure and hypertension
 Acceptable and sustainable methods to promote
quality improvement activities within general
practice
 Purpose-built extraction and feedback tools that can
calculate complex indicators useful to monitor
prescribing behaviour, promote change and enable
evaluation of educational interventions
 Opportunity to refine clinical indicators to better
reflect quality of clinical care and outcomes of
prescribing behaviour.
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